Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion.
Gelander. L L; Lindstedt. G G; Selstam. G G; Wide. L L; Albertsson-Wikland. K K
Key Findings
- Both GHRH 1â40 and GHRH 1â29 produced comparable peak GH levels (â90â94âŻmU/L) after a 1âŻÂ”g/kg IV injection.
- GHRH 1â29 caused a modest, shortâterm increase in prolactin, luteinizing hormone, and follicleâstimulating hormone.
- Individual GH responses varied widely (increase of 1â153âŻmU/L), indicating personal variability.
Practical Outcomes
- The study suggests the shorter GHRH 1â29 is just as effective as the fullâlength version for an acute GH surge, which could be useful if you prefer a smaller peptide. However, because the experiment was done intravenously in children, you cannot directly apply the dose or safety profile to adult subâcutaneous protocols. Use this as a proofâofâconcept that GHRH 1â29 works, but seek adultâspecific data before incorporating it into longevity or performance regimens.
Summary
In a small study of short preâpubertal kids, a single IV dose of either the fullâlength GHRH (1â40) or the shorter version (1â29) caused a similar, sharp rise in growth hormone. The shorter peptide also gave a tiny, shortâlived bump in prolactin, LH and FSH. The work shows the two peptides are equally potent for an acute GH spike, but it was done in children using an IV route, not in adults or with the typical subâQ dosing biohackers use.
Abstract
We administered two different growth hormone-releasing hormones (GHRH) to 20 short, prepubertal children who had spontaneous secretion of growth hormone (GH), assessed from 24-hour GH secretion profiles (72 sampling periods of 20 min). We compared one i.v. injection of 1 microgram/kg of GHRH 1-40 with that of GHRH 1-29 regarding serum concentrations of GH, prolactin, luteinizing hormone, follicle-stimulating hormone and IGF-I. The children were allocated to two groups without statistical randomization. Both groups were given both peptides, with at least 1 week in between. The first group started with GHRH 1-40, the other with GHRH 1-29. The peptides both induced an increased serum concentration of GH of the same magnitude: mean maximal peak of 89 +/- 12 mU/l after GHRH 1-40 and 94 +/- 10 mU/l after GHRH 1-29 (n.s.). The mean difference in maximum serum GH concentration in each child after injection was 52 +/- 9 mU/l, range 1-153 mU/l. GHRH 1-29 also induced a short-term, small increase in the concentrations of prolactin (p less than 0.05), luteinizing hormone (p less than 0.01) and follicle-stimulating hormone (p less than 0.05). We conclude that the shorter sequence GHRH 1-29, when given in a dose of 1 microgram/kg, gives a rise in serum concentration of GH similar to that after the native form GHRH 1-40.
Study Information
pubmed
1989
10.1159/000181119
2